In a phase II clinical trial conducted by Zhu et al., 57 patients diagnosed with advanced biliary tract cancer (BTC) were treated with Lenvatinib in combination with a PD-1/PD-L1 inhibitor and GEMOX chemotherapy. The gene discussed is PDCD1; the disease is biliary tract neoplasm.